《结核病政策指南制订过程中发现的证据和研究缺口(第2版)》解读——结核病相关共病

doi:10.19982/j.issn.1000-6621.20240076

中国防痨杂志 ›› 2024, Vol. 46 ›› Issue (6): 618-624.doi: 10.19982/j.issn.1000-6621.20240076

《结核病政策指南制订过程中发现的证据和研究缺口(第2版)》解读——结核病相关共病

刘桂珍¹, 邓国防²()

¹赣南医科大学第一临床医学院,赣州 341000
²深圳市第三人民医院/国家感染性疾病临床医学研究中心/广东省结核病临床医学研究中心/深圳市结核病临床医学研究中心,深圳 518000

收稿日期:2024-03-01 出版日期:2024-06-10 发布日期:2024-06-03
通信作者: 邓国防,Email:jxxk1035@yeah.net
基金资助:
国家自然科学基金(82070016);国家重点研发计划(2023YFC2306700);国家重点研发计划(2023YFC2306703);广东省结核病临床医学研究中心项目(2020B1111170014);深圳市结核病临床研究中心(20210617141509001);深圳市科创委基金(KCXFZ20211020163545004);深圳市科创委基金(RCJC20221008092726022);深圳市第三人民医院科研基金(G2021010);深圳市第三人民医院科研基金(G2021015);深圳市第三人民医院科研基金(G2021023);深圳市第三人民医院科研基金(G2022155)

Interpretation of Evidence and research gaps identified during development of policy guidelines for tuberculosis (Second edition): tuberculosis related comorbidity

Liu Guizhen¹, Deng Guofang²()

¹The First Clinical Medical College of Gannan Medical University, Jiangxi Province, Ganzhou 341000, China
²Shenzhen Third People’s Hospital/National Clinical Research Center for Infectious Disease (Shenzhen)/Guangdong Provincial Clinical Research Center for Tuberculosis/Shenzhen Clinical Research Center for Tuberculosis, Shenzhen 518000, China

Received:2024-03-01 Online:2024-06-10 Published:2024-06-03
Contact: Deng Guofang, Email: jxxk1035@yeah.net
Supported by:
National Natural Science Foundation of China(82070016);National Key Research and Development Program of China(2023YFC2306700);National Key Research and Development Program of China(2023YFC2306703);Guangdong Provincial Clinical Research Center for Tuberculosis Project(2020B1111170014);Shenzhen Clinical Research Center for Tuberculosis(20210617141509001);Shenzhen Scientific and Technological Foundation(KCXFZ20211020163545004);Shenzhen Scientific and Technological Foundation(RCJC20221008092726022);Shenzhen Third People’s Hospital Research Fund(G2021010);Shenzhen Third People’s Hospital Research Fund(G2021015);Shenzhen Third People’s Hospital Research Fund(G2021023);Shenzhen Third People’s Hospital Research Fund(G2022155)

摘要/Abstract

摘要：

应对结核病患者共病和相关危险因素对于终止结核病流行至关重要。世界卫生组织2023年发布了《结核病政策指南制订过程中发现的证据和研究缺口(第2版)》,其中,关于结核病相关共病方面,主要列出了结核分枝杆菌/HIV双重感染、营养支持与关怀,以及注射吸毒人群等方面的研究缺口。本文中,笔者就上述研究缺口内容进行解读,并总结我国目前在上述方面的研究进展,以供相关专业工作者参考。

关键词: 结核, 共病现象, 总结性报告(主题)

Abstract:

Addressing comorbidities and associated risk factors in patients with tuberculosis is crucial for eradicating the disease. In 2023, the World Health Organization released the second edition of Evidence and research gaps identified during development of policy guidelines for tuberculosis, which highlights the principal research gaps in tuberculosis-related comorbidities, notably in Mycobacterium tuberculosis/HIV co-infection, nutritional support and care, and among populations of injecting drug users. In this article, the author interprets these identified research gaps and summarizes China’s current research advancements in these areas, providing insights for professionals engaged in related fields.

Key words: Tuberculosis, Comorbidity, Summary report (topic)

中图分类号:

刘桂珍, 邓国防. 《结核病政策指南制订过程中发现的证据和研究缺口(第2版)》解读——结核病相关共病[J]. 中国防痨杂志, 2024, 46(6): 618-624. doi: 10.19982/j.issn.1000-6621.20240076

Liu Guizhen, Deng Guofang. Interpretation of Evidence and research gaps identified during development of policy guidelines for tuberculosis (Second edition): tuberculosis related comorbidity[J]. Chinese Journal of Antituberculosis, 2024, 46(6): 618-624. doi: 10.19982/j.issn.1000-6621.20240076

参考文献 36

[1]	World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization, 2023.
[2]	Bagcchi S. WHO’s Global Tuberculosis Report 2022. Lancet Microbe, 2023, 4(1): e20. doi:10.1016/S2666-5247(22)00359-7.
[3]	World Health Organization. Evidence and research gaps identified during development of policy guidelines for tuberculosis.2nd ed. Geneva: World Health Organization, 2023.
[4]	Fennelly KP, Martinez L, Mandalakas AM. Tuberculosis: First in Flight. Am J Respir Crit Care Med, 2022, 205(3): 272-274. doi:10.1164/rccm.202111-2513ED.
[5]	World Health Organization. Global Tuberculosis Report 2021. Geneva: World Health Organization, 2021.
[6]	Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc, 2016, 19(1): 20714. doi:10.7448/IAS.19.1.20714. pmid: 26765347
[7]	Gupta RK, Lucas SB, Fielding KL, et al. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS, 2015, 29(15): 1987-2002. doi:10.1097/QAD.0000000000000802. pmid: 26266773
[8]	Montes K, Atluri H, Silvestre Tuch H, et al. Risk factors for mortality and multidrug resistance in pulmonary tuberculosis in Guatemala: A retrospective analysis of mandatory reporting. J Clin Tuberc Other Mycobact Dis, 2021, 25: 100287. doi:10.1016/j.jctube.2021.100287.
[9]	Lönnroth K, Raviglione M. The WHO’s new End TB Strategy in the post-2015 era of the Sustainable Development Goals. Trans R Soc Trop Med Hyg, 2016, 110(3): 148-150. doi:10.1093/trstmh/trv108.
[10]	Sinha P, Davis J, Saag L, et al. Undernutrition and Tuberculosis: Public Health Implications. J Infect Dis, 2019, 219(9): 1356-1363. doi:10.1093/infdis/jiy675. pmid: 30476125
[11]	Ma JJ, Guo YJ, Li Z, et al. Prevalence and prognostic significance of malnutrition risk in patients with pulmonary tuberculosis: A hospital-based cohort study. Front Public Health, 2022, 10: 1039661. doi:10.3389/fpubh.2022.1039661.
[12]	Meijerink H, Wisaksana R, Lestari M, et al. Active and latent tuberculosis among HIV-positive injecting drug users in Indonesia. J Int AIDS Soc, 2015, 18(1): 19317. doi:10.7448/IAS.18.1.19317.
[13]	Verrall AJ, Netea MG, Alisjahbana B, et al. Early clearance of Mycobacterium tuberculosis: a new frontier in prevention. Immunology, 2014, 141(4): 506-513. doi:10.1111/imm.12223. pmid: 24754048
[14]	Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis, 2009, 48(1): 72-82. doi:10.1086/594126. pmid: 19046064
[15]	Niveau G. Prevention of infectious disease transmission in correctional settings: a review. Public Health, 2006, 120(1): 33-41. doi:10.1016/j.puhe.2005.03.017. pmid: 16129465
[16]	Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med, 2012, 9(7): e1001270. doi:10.1371/journal.pmed.1001270.
[17]	中国性病艾滋病防治协会HIV合并结核病专业委员会. 人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识. 中华传染病杂志, 2022, 40(1): 6-19. doi:10.3760/cma.j.cn311365-20211105-00387.
[18]	Sun J, Liu L, Shen J, et al. Trends in baseline CD 4 cell counts and risk factors for late antiretroviral therapy initiation among HIV-positive patients in Shanghai, a retrospective cross-sectional study. BMC Infect Dis, 2017, 17(1): 285. doi:10.1186/s12879-017-2398-5.
[19]	Liu L, Zhang R, Tang Y, et al. The importance of non-tuberculous mycobacteria identification in Chinese patients infected with HIV. Biosci Trends, 2018, 12(5): 515-516. doi:10.5582/bst.2018.01254.
[20]	Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet, 2010, 376(9738): 355-366. doi:10.1016/S0140-6736(10)60832-X. pmid: 20650513
[21]	Tellez-Navarrete NA, Ramon-Luing LA, Muñoz-Torrico M, et al. Malnutrition and tuberculosis: the gap between basic research and clinical trials. J Infect Dev Ctries, 2021, 15(3): 310-319. doi:10.3855/jidc.12821.
[22]	Li A, Yuan SY, Li QG, et al. Prevalence and risk factors of malnutrition in patients with pulmonary tuberculosis: a systematic review and meta-analysis. Front Med (Lausanne), 2023, 10: 1173619. doi:10.3389/fmed.2023.1173619.
[23]	Feleke BE, Feleke TE, Biadglegne F. Nutritional status of tuberculosis patients, a comparative cross-sectional study. BMC Pulm Med, 2019, 19(1): 182. doi:10.1186/s12890-019-0953-0. pmid: 31638950
[24]	Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med, 1979, 139(3): 337-339. pmid: 426578
[25]	Alpert PL, Munsiff SS, Gourevitch MN, et al. A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. Clin Infect Dis, 1997, 24(4): 661-668. doi:10.1093/clind/24.4.661. pmid: 9145741
[26]	郭新枝, 陈裕. 吸毒对肺结核患者病情的影响. 医药论坛杂志, 2003, 24(20): 11-12. doi:10.3969/j.issn.1672-3422.2003.20.006.
[27]	谭毅刚, 陈小冰. 毒品依赖者患肺结核临床及预后分析. 实用医学杂志, 2001, 17(7): 624. doi:10.3969/j.issn.1006-5725.2001.07.028.
[28]	Rusen ID, Yuan L, Millson ME. Prevalence of Mycobacterium tuberculosis infection among injection drug users in Toronto. CMAJ, 1999, 160(6): 799-802.
[29]	中华医学会感染病学分会艾滋病学组, 中华医学会热带病与寄生虫学分会艾滋病学组. HIV合并结核分枝杆菌感染诊治专家共识. 中华临床感染病杂志, 2017, 10(2): 81-90. doi:10.3760/cma.j.issn.1674-2397.2017.02.001.
[30]	Soeters HM, Napravnik S, Patel MR, et al. The effect of tuberculosis treatment on virologic and CD4⁺ cell count response to combination antiretroviral therapy: a systematic review. AIDS, 2014, 28(2): 245-255. doi:10.1097/01.aids.0000434936.57880.cd. pmid: 24072197
[31]	孙建军, 卢洪洲. 艾滋病合并结核病的诊治近况. 国际流行病学传染病学杂志, 2020, 47(2): 73-76. doi:10.3760/cma.j.cn331340-20200301-00041.
[32]	Ren Z, Zhao F, Chen H, et al. Nutritional intakes and associated factors among tuberculosis patients: a cross-sectional study in China. BMC Infect Dis, 2019, 19(1): 907. doi:10.1186/s12879-019-4481-6. pmid: 31664922
[33]	Chen W, Ding Q, Zhang SK, et al. Nutritional status in patients with active pulmonary tuberculosis and new nutritional risk screening model for active tuberculosis: a national, multicenter, cross-sectional study in China. J Thorac Dis, 2023, 15(5): 2779-2799. doi:10.21037/jtd-23-623. pmid: 37324100
[34]	Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis, 2016, 63(7): e147-e195. doi:10.1093/cid/ciw376.
[35]	秦璐. 反馈式健康教育结合强化心理护理对肺结核吸毒患者心理状态及应对方式的影响. 中国现代药物应用, 2019, 13(7):185-187. doi:10.14164/j.cnki.cn11-5581/r.2019.07.106.
[36]	国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 国家代谢性疾病临床医学研究中心, 等. 结核病与糖尿病共病的治疗管理专家共识. 中国防痨杂志, 2021, 43(1): 12-22. doi:10.3969/j.issn.1000-6621.2021.01.004.

《结核病政策指南制订过程中发现的证据和研究缺口(第2版)》解读——结核病相关共病

Interpretation of Evidence and research gaps identified during development of policy guidelines for tuberculosis (Second edition): tuberculosis related comorbidity

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	李敏, 姚宇珊, 乔海霞, 雷红. 肺结核与肠道菌群的相关性及治疗策略[J]. 中国防痨杂志, 2025, 47(4): 520-526.
[2]	李锦浩, 胡冬梅, 徐彩红. 结核病防治医务工作者开展预防性抗结核治疗工作意愿调查及影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 398-407.
[3]	冯畏, 郑海伦, 孟炜丽, 罗萍. 2018—2023年北京市西城区结核病防治机构登记管理肺结核患者到位前漏报情况分析[J]. 中国防痨杂志, 2025, 47(4): 439-443.
[4]	郝明晓, 米洁, 许宗仪. 延续性护理路径在结核性脑膜炎患者中的应用效果分析[J]. 中国防痨杂志, 2025, 47(4): 477-481.
[5]	宋云林, 布祖克拉·阿布都艾尼, 王桂荣, 张继园, 鲁晓擘. 钙结合蛋白S100A12与中性粒细胞胞外诱捕网形成在重症肺结核患者肺损伤中作用机制研究进展[J]. 中国防痨杂志, 2025, 47(4): 513-519.
[6]	胡一凡, 杜博平, 吴亚东, 朱传智, 张蓝月, 贾红彦, 孙琦, 潘丽萍, 张宗德, 李自慧. Mce4C蛋白参与结核分枝杆菌摄取利用胆固醇的实验研究[J]. 中国防痨杂志, 2025, 47(4): 444-453.
[7]	盛杰, 洪凯峰, 米尔扎提·艾沙, 唐伟, 地里下提·阿不力孜. 白细胞介素22和p38 MAPK信号通路抑制骨关节结核骨质破坏的作用机制研究[J]. 中国防痨杂志, 2025, 47(4): 454-459.
[8]	尚希钰, 张慧芳, 曹玉清, 熊一白, 纪鑫毓, 田雅欣, 李佳佳, 王倪, 马艳. 基于文献计量学的结核病中医药基础研究全球研究现状及热点分析[J]. 中国防痨杂志, 2025, 47(4): 482-497.
[9]	秦丽莉, 杨澄清, 麦洪珍, 徐齐峰, 薛新颖, 路希维. 结核后肺曲霉病的临床诊疗研究进展[J]. 中国防痨杂志, 2025, 47(4): 498-504.
[10]	罗莉, 罗林紫, 尹曲华, 周磊, 卢志斌, 丁衍, 肖阳宝. 淋巴结瘘型气管支气管结核的支气管镜下诊疗进展[J]. 中国防痨杂志, 2025, 47(4): 505-512.
[11]	中国防痨协会结核病控制专业分会, 中国防痨协会青年分会, 《中国防痨杂志》编辑委员会. 中国结核病数字服药依从性技术应用指南[J]. 中国防痨杂志, 2025, 47(4): 385-397.
[12]	吴璇, 张艳秋, 徐吉英, 孟丹, 孙定勇. 2019—2023年河南省肺结核合并糖尿病患者治疗转归影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 425-431.
[13]	王颖超, 刘唯夷, 姬秀秀, 尚雪恬, 贾红彦, 张蓝月, 孙琦, 杜博平, 朱传智, 潘丽萍, 张宗德. 结核病患者外周血单个核细胞内环状RNA表达谱分析及诊断标识的鉴定[J]. 中国防痨杂志, 2025, 47(4): 460-470.
[14]	朱明智, 邵燕琴, 范大鹏, 刘立宾, 梅宾, 戴玲珊, 蔡龙. 尿液脂阿拉伯甘露聚糖抗原检测对肺外结核的诊断价值[J]. 中国防痨杂志, 2025, 47(4): 471-476.
[15]	黄伟强, 袁楚楚, 陈星星, 商会会, 徐雅, 胡明. 康替唑胺替代利奈唑胺方案治疗耐药结核病一例[J]. 中国防痨杂志, 2025, 47(4): 527-530.